Physician Adoption of Live Video Detailing Has Doubled Since 2008

Manhattan ResearchLive video detailing has made a strong comeback after a false start in the early 2000s, according to pharmaceutical and healthcare market research company Manhattan Research's ePharma Physician® v10.0 study. Physician adoption of live video detailing has more than doubled in the past two years, according to the study. A considerable share of these users self-report that their prescribing behavior is influenced by these programs, which is critical feedback for marketers concerned about the return on investment of this channel.

"Live video detailing is certainly a success story so far, which is great news for companies looking to optimize their sales strategy," said Monique Levy, Senior Director of Research at Manhattan Research. "After this initial surge in participation, however, we expect adoption will likely plateau for the next few years while companies do a better job at relaying the value proposition and optimize targeting to non-users."

Complimentary Recorded Webinar
ePharma Physician® provides key intelligence to pharma and biotech companies, agencies, and healthcare publishers connecting with physicians through digital channels. The study provides in-depth data and analysis on video detailing, including reach and satisfaction rankings of e-detailing and video detailing programs by company. Additional research topics include the physician channel mix, iPad use and interest, relationship with reps, various types of online promotion, visitation to online pharmaceutical properties, customer service, electronic sampling, and much more.

For an overview of ePharma Physician® research topics and subscription benefits in a complimentary recorded webinar, please visit http://www.manhattanresearch.com/webinars/epp.

About ePharma Physician®
ePharma Physician® v10.0 was conducted via online survey in Q2 2010 among 1,713 U.S. physicians who have looked online for pharmaceutical information, visited a pharmaceutical or biotech product or corporate website, or participated in an e-detailing program from a pharmaceutical or biotech company in the past 12 months. Clients can cut the data to gain insights for more than 25 specialties.

For additional information, please visit http://www.manhattanresearch.com/epp.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a global pharmaceutical and healthcare market research and strategic advisory firm and conducts annual research studies covering eHealth trends among physicians and consumers. Broad consumer and physician research is complemented by analysis for over 100 consumer therapeutic segments and physician specialist segments. For more information, please contact This email address is being protected from spambots. You need JavaScript enabled to view it. or visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com.

Most Popular Now

Pfizer announces positive top-line results from Ph…

Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) evaluating fidanacogene elaparvovec, an investigational ...

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

COVID-19 vaccines, prior infection reduce transmis…

Vaccination and boosting, especially when recent, helped to limit the spread of COVID-19 in California prisons during the first Omicron wave, according to an analysis by ...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

Enzyme that protects against viruses could fuel ca…

An enzyme that defends human cells against viruses can help drive cancer evolution towards greater malignancy by causing myriad mutations in cancer cells, according to a ...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...